Can low T3 and higher TSH raise LDL cholesterol, LDL-P, and apoB?

Thyroid hormones are critical systemic regulators of lipid metabolism, directly modulating the hepatic pathways responsible for clearing atherogenic lipoproteins from circulation.

Mechanistic pathways of thyroid-mediated lipid regulation

• Direct and indirect T3 transcriptional control: Triiodothyronine ($T_3$) directly stimulates low-density lipoprotein receptor (LDLR) transcription by binding to the thyroid hormone receptor beta ($\text{TR}\beta$) on thyroid hormone response elements (TREs) in the LDLR promoter. Additionally, $T_3$ upregulates sterol regulatory element-binding protein 2 (SREBP-2) gene expression and activity. Low $T_3$ availability compromises both of these pathways, leading to suppressed LDLR transcription.
• TSH-mediated LDLR degradation: Independently of thyroid hormone levels, elevated thyroid-stimulating hormone (TSH) binds to hepatocyte receptors and upregulates proprotein convertase subtilisin/kexin type 9 (PCSK9) expression. PCSK9 physically targets cell-surface LDLR for lysosomal degradation, reducing its availability and functional clearance capacity.

Downstream clinical lipid consequences

• Impaired clearance kinetics: The synergistic effect of low $T_3$ and high TSH significantly reduces hepatic LDLR activity. This impairs receptor-mediated endocytosis of circulating low-density lipoproteins, mimicking the clearance deficits seen in genetic disorders of lipid metabolism like familial hypercholesterolemia.
• Atherogenic particle accumulation: Because hepatic clearance is compromised, the residence time of circulating lipoproteins is prolonged. This drives parallel elevations in LDL cholesterol (LDL-C) mass, LDL particle number (LDL-P), and apolipoprotein B-100 (apoB) concentrations, as each atherogenic LDL particle structurally contains exactly one apoB molecule.

Bottom line

• Key takeaway: Low $T_3$ availability and elevated TSH synergistically suppress cell-surface LDLR activity by reducing its transcription (via $T_3$/$\text{TR}\beta$/SREBP-2) and accelerating its degradation (via TSH/PCSK9). This impairment in hepatic clearance directly causes the accumulation of circulating LDL-C, LDL-P, and apoB.